BioNxt Solutions Inc. (CVE:BNXT)

BRIEF

published on 10/30/2025 at 08:10, 5 months 10 days ago

BioNxt Solutions Inc. Advances Patent for Cancer Drug Delivery

Multiple Sclerosis Drug Delivery BioNxt Solutions Eurasian Patent Patent Strategy
PRESS RELEASE

published on 10/30/2025 at 08:05, 5 months 10 days ago

BioNxt Reports "Readiness to Grant" Patent Notification from the Eurasian Patent Organization
BioNxt Solutions Inc. receives "Readiness to Grant" notification from EAPO for comprehensive patent application on sublingual delivery of anticancer drugs for autoimmune neurodegenerative diseases, including lead product BNT23001 for MS treatment. Patent protection strengthens commercialization strategy

BioNxt Solutions Inc. Patent Application Sublingual Drug Delivery Anticancer Drugs EAPO
BRIEF

published on 10/21/2025 at 09:10, 5 months 19 days ago

BioNxt Initiates Sublingual Cladribine Study for MS Treatment Optimization

Multiple Sclerosis Bioavailability Drug Delivery Bioequivalence Study Sublingual Cladribine
PRESS RELEASE

published on 10/21/2025 at 09:05, 5 months 19 days ago

BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study
BioNxt Solutions Inc. announces a large-mass animal bioequivalence study for sublingual Cladribine formulation, targeting multiple sclerosis treatment, to optimize dosage parameters for upcoming human study

BioNxt Solutions Inc. Multiple Sclerosis Treatment Bioequivalence Study Drug Delivery Technologies Sublingual Cladribine Formulation
BRIEF

published on 10/10/2025 at 01:55, 5 months 30 days ago

BioNxt Solutions Addresses AGM Voting Amid Postal Strike

AGM Voting Marketing Campaign Canada Post Strike Proxy Submission
PRESS RELEASE

published on 10/10/2025 at 01:50, 5 months 30 days ago

BioNxt Solutions Provides Update To Annual General Meeting Matters Due To Canadian Postal Strike And IR Activities
BioNxt Solutions Inc. provides alternative voting options for shareholders due to Canada Post mail strike. Annual general meeting details and proxy voting instructions shared

Annual General Meeting Shareholders BioNxt Solutions Inc. Proxy Voting Voting Options
BRIEF

published on 10/09/2025 at 09:10, 6 months ago

BioNxt Completes Fast-Track Patent Filing for MS Treatment

Multiple Sclerosis Cladribine Patent Filing BioNxt Solutions Sublingual Delivery
PRESS RELEASE

published on 10/09/2025 at 09:05, 6 months ago

BioNxt Completes "Fast-Track" US Track One Patent Filing for Sublingual Delivery of Cladribine for the Treatment of Multiple Sclerosis
BioNxt Solutions Inc. completes Track One priority patent filing with USPTO for sublingual thin-film cladribine formulation (BNT23001) targeting MS & other autoimmune diseases. Strategic move to strengthen IP position & advance regulatory approvals

BioNxt Solutions Inc. Multiple Sclerosis Patent Filing Sublingual Thin-Film Cladribine Formulation
BRIEF

published on 10/02/2025 at 09:10, 6 months 7 days ago

BioNxt Advances Targeted Chemotherapy Drug Delivery Platform

Biopharmaceutical Drug Delivery Research Advancements BioNxt Solutions Targeted Chemotherapy
PRESS RELEASE

published on 10/02/2025 at 09:05, 6 months 7 days ago

BioNxt Reports Update on Targeted Chemotherapy Drug Delivery Platform
BioNxt Solutions Inc. reports significant advancement in targeted chemotherapy delivery platform and upcoming definitive agreement. Proprietary technology aims at 10-fold increase in therapeutic effect while safeguarding healthy cells

BioNxt Solutions Inc. Oncology Treatments Chemotherapy Delivery Platform Targeted Drug Delivery System Therapeutic Effect

Published on 04/09/2026 at 19:15, 2 hours 43 minutes ago

Murchison Minerals Announces Adoption of Quarterly Reporting Exemption Under Coordinated Blanket Order 51-933
Published on 04/09/2026 at 16:00, 5 hours 58 minutes ago

Banff Half Marathon Completes 2025 Emissions Assessment, Supporting Climate Action with Karbon-X
Published on 04/09/2026 at 14:40, 7 hours 18 minutes ago

Silver X Delivers Production Growth During the First Quarter of 2026
Published on 04/09/2026 at 14:00, 7 hours 58 minutes ago

Orogen Royalties Announces Mineral Reserve and Resource Update on Producing Ermitaño Royalty
Published on 04/09/2026 at 13:30, 8 hours 28 minutes ago

Datametrex Receives $6M Purchase Order for Data Centre from Fortune 500 Conglomerate

View all ACCESSWIRE

Published on 04/09/2026 at 21:01, 56 minutes ago

GEVELOT S.A.: PRESS RELEASE CLOSING OF 2025 ACCOUNTS
Published on 04/09/2026 at 20:03, 1 hour 54 minutes ago

Annual General Meeting approves all proposals
Published on 04/09/2026 at 18:15, 3 hours 42 minutes ago

REPLY: Launch of a share buyback program for a maximum number of 3,607,950 shares
Published on 04/09/2026 at 15:59, 5 hours 58 minutes ago

Cairn Homes Plc: Holding(s) in Company
Published on 04/09/2026 at 15:57, 6 hours ago

Cairn Homes Plc: Holding(s) in Company

View all EQS

Published on 04/09/2026 at 18:35, 3 hours 23 minutes ago

Availability of proxy documents for the Combined General Meeting of April 30, 2026
Published on 04/09/2026 at 17:35, 4 hours 23 minutes ago

SUEZ - FY 2025
Published on 04/09/2026 at 15:57, 6 hours ago

Filing of CNP Assurances SA 2025 universal registration document and 2025 Solvency and Financial Condition Reports
Published on 04/09/2026 at 07:00, 14 hours 58 minutes ago

bioMérieux Unveils its BIOFIRE® SPOTFIRE® Molecular Testing Solution for the Pharmaceutical Industry, Redefining Rapid Mycoplasma Testing
Published on 04/08/2026 at 18:02, 1 day 3 hours ago

Publication of the 2025 Universal Registration Document

View all LES ECHOS COMFI WIRE

News